Skip to Content
Merck
  • The sustained increase of plasma fibrinogen during ischemic stroke predicts worse outcome independently of baseline fibrinogen level.

The sustained increase of plasma fibrinogen during ischemic stroke predicts worse outcome independently of baseline fibrinogen level.

Inflammation (2014-02-18)
Marta Swarowska, Aleksandra Janowska, Agnieszka Polczak, Aleksandra Klimkowicz-Mrowiec, Joanna Pera, Agnieszka Slowik, Tomasz Dziedzic
ABSTRACT

Hyperfibrinogenemia at the beginning of ischemic stroke is associated with poor outcome. We hypothesized that the sustained increase of plasma fibrinogen during stroke predicts outcome independently of baseline fibrinogen concentration. We included 266 patients with first-ever ischemic stroke in whom plasma fibrinogen level was measured on days 1, 7, and 14. The sustained fibrinogen's increase was defined as the persistent elevation of fibrinogen's concentration on days 7 and 14 by at least 20 % compared to the level on day 1. The functional outcome on day 30 was assessed using modified Rankin Scale (mRS). Favorable outcome was defined as mRS 0-1. The sustained increase of fibrinogen was found in 17 % of patients. On multivariate logistic regression analysis adjusted for age, NIHSS score, baseline fibrinogen >2.66 mmol/L, presence of infection, and hyperglycemia, the sustained fibrinogen's level was associated with reduced chance of favorable outcome (OR: 0.17, 95 % CI: 0.06-0.48, P < 0.01).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Fibrinogen from human plasma, 35-65% protein (≥90% of protein is clottable).